Swiss Regulatory Authority Grants Accelerated Assessment of Planned Market Authorization Application for Ceftobiprole
Swissmedic accelerated assessment designation is designed to expedite the availability of treatments that address high medical needs and is granted provided all of the following criteria are fulfilled: the therapy must have promising potential for the treatment of a severely debilitating or life-threatening disease, existing therapies are insufficient or not available, and a high therapeutic benefit is expected through the use of the drug.
Ceftobiprole (BAL5788), Basilea's lead antibacterial product is specially designed to bind the penicillin-resistant targets in many Gram-positive cocci, resulting in bactericidal activity towards methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP). Ceftobiprole has demonstrated a broad-spectrum profile targeting other Gram-positive as well as Gram-negative pathogens. In addition it has shown a low potential to select resistance in vitro.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.